EUVIMEDEUVIMED entdecken
Open Access

An inhibitor of UHM splicing factors exerts anti-leukemic activity by altering cell cycle progression and reducing lysosome acidification

Mona Kazemi Sabzvar, Eun Bee Cho, Xinrui Yuan, Arda Durmaz, Amol D Patil, Daniel M Collier, Jianxiong Jiang, Valeria Visconte, Chao-Yie Yang

Cellular Signalling · 2025-12 · 136 · 112112

DOI: 10.1016/j.cellsig.2025.112112 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Signalling, 2025-12. Verfasst von Mona Kazemi Sabzvar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN 38163, United States of Americ…. Hauptthemen laut MEDLINE: Lysosomes, Leukemia, RNA Splicing Factors, Cell Cycle. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NCI NIH HHS, National Institute of Neurological Disorders and Stroke.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mature mRNAs are generated by spliceosomes that recruit factors to aid RNA splicing in which introns are removed and exons joined. Among the splicing factors, a family of proteins contain a homologous U2 Auxiliary Factor (U2AF) Homology Motif (UHM) to bind with factors containing U2AF ligand motifs (ULM) and recruit them to regulate 3' splice site selection. Mutations and overexpression of UHM splicing factors are frequently found in cancers. Although a few UHM inhibitors have been reported, their activities in cancer cells were not investigated. Here, we studied our recently discovered UHM inhibitor, SF-153, that targeted RBM39 and SPF45, and found SF-153 exerted anti-tumor activities in three leukemia cell lines. In the cell cycle and apoptosis analysis, SF-153 induces p53 mediated DNA damage response to give protracted S phase in NKM-1 but p53-independent G1 arrest in p53nullK562 cells. RNA-seq analysis of NKM-1 treated with SF-153 revealed downregulation of Myc target genes and genes involved in nucleotides and protein synthesis. Western blot analysis confirmed decreased proteins levels of Myc, EEF1A1, and MCM7 suggesting reduced DNA replication activity in NKM-1. Transcript analysis derived from the RNA-seq data indicated six genes changed isoform patterns but downregulation of only one DOCK2 isoform was confirmed in qRT-PCR. RNA-seq analysis additionally uncovered that SF-153 impaired lysosome acidification and inhibited autophagy to enhance the anti-leukemic activities. Taken together, our study characterized the multimodal mechanisms of inhibition by SF-153 in leukemia cells and laid the foundation for studying selective UHM inhibitors in future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LysosomesLeukemiaRNA Splicing FactorsCell CycleAntineoplastic AgentsHumansCell Line, TumorRNA-Binding ProteinsApoptosisDNA DamageTumor Suppressor Protein p53

Stichwörter der Autor:innen

Cell cycleDual inverted selective plane of illumination microscopeLysosome acidificationSmall-molecule inhibitorsSplicing factorU2AF homology motif

Substanzen

RNA Splicing FactorsRNA-Binding ProteinsAntineoplastic AgentsTumor Suppressor Protein p53

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN 38163, United States of America.
  • Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, United States of America.
  • Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN 38163, United States of America. Electronic address: cyang26@uthsc.edu.

Förderung

  • NINDS NIH HHS
  • NCI NIH HHS
  • National Institute of Neurological Disorders and Stroke
  • National Institutes of Health National Cancer Institute
  • National Institutes of Health
  • Health Science Center, University of Tennessee

Zitieren

APA

Sabzvar, M. K., Cho, E. B., Yuan, X., Durmaz, A., Patil, A. D., Collier, D. M., Jiang, J., Visconte, V., & Yang, C. Y. (2025). An inhibitor of UHM splicing factors exerts anti-leukemic activity by altering cell cycle progression and reducing lysosome acidification. Cellular Signalling, 136, 112112. https://doi.org/10.1016/j.cellsig.2025.112112

Vancouver

Sabzvar MK, Cho EB, Yuan X, Durmaz A, Patil AD, Collier DM, et al. An inhibitor of UHM splicing factors exerts anti-leukemic activity by altering cell cycle progression and reducing lysosome acidification. Cellular Signalling. 2025;136:112112. doi:10.1016/j.cellsig.2025.112112

BibTeX
@article{Sabzvar2025,
  author = {Sabzvar, Mona Kazemi and Cho, Eun Bee and Yuan, Xinrui and Durmaz, Arda and Patil, Amol D and Collier, Daniel M and Jiang, Jianxiong and Visconte, Valeria and Yang, Chao-Yie},
  title = {An inhibitor of UHM splicing factors exerts anti-leukemic activity by altering cell cycle progression and reducing lysosome acidification},
  journal = {Cellular Signalling},
  year = {2025},
  volume = {136},
  pages = {112112},
  doi = {10.1016/j.cellsig.2025.112112}
}
Kostenlos starten →